Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tobacco Use Disorder: early-phase trial registry
19 of 75 indexed Tobacco Use Disorder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #178 of 28,707 conditions by registered trial count.
75 US clinical trials · 19 currently recruiting · #178 of 28,707 conditions by registered trial count
Tobacco Use Disorder: 75 US clinical trials tracked, 19 recruiting.
Tobacco Use Disorder is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 34 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 7 of these trials.
Enrollment posture brief
Registry condition tobacco-use-disorder
OPEN 19 | RECR 25% | LATE 9 | EARLY 34 | RANK #178 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Overweight (25% recruiting · 198 trials)
Tobacco Use Disorder lists 19 open slots (25% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tobacco Use Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tobacco Use Disorder is recruiting below its size-band peers.
19 of 75 indexed trials (25.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Tobacco Use Disorder trials is spread across many organizations.
National Institute on Drug Abuse (NIDA) accounts for 7 of 75 trials (9.3%). 36 distinct sponsors appear on at least one study for this condition label.
-
Typical Tobacco Use Disorder enrolment sits around 108 participants.
Median target enrolment is 108 among the 71 trials that report a genuine target (sentinel values excluded). 32 of those (45.1%) plan for fewer than 100 participants.
-
Tobacco Use Disorder research is mostly interventional.
73 interventional and 2 observational studies make up this index (97.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
75 total, page 2 of 2
Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults
University of Minnesota
NCT01497158
Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
University of Minnesota
NCT00711100
Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy
NYU Langone Health
NCT02628964
Effect of Galantamine on Short-term Abstinence
University of Pennsylvania
NCT01669538
Examining a Text Message Intervention for Smoking Cessation
The Miriam Hospital
NCT01166464
Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit
Rutgers, The State University of New Jersey
NCT01308736
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
University of Missouri-Columbia
NCT03960138
Persistence-Targeted Smoking Cessation
Rutgers, The State University of New Jersey
NCT01654107
Text Message Support to Prevent Smoking Relapse
Miami University
NCT02968095
Medicinal Nicotine for Preventing Cue Induced Craving
University of Minnesota
NCT02347605
A Comparison of Bupropion SR and Placebo for Smoking Cessation
University of Maryland, Baltimore
NCT00176449
Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use
University of Minnesota
NCT03402243
Progesterone for Smoking Relapse Prevention Following Delivery
Yale University
NCT01972464
Tobacco Approach Avoidance Training for Adolescent Smokers-1
Yale University
NCT01625767
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
University of Chicago
NCT00967005
Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3
New York State Psychiatric Institute
NCT00136786
Reduced Nicotine Cigarette Purchasing Decisions
Johns Hopkins University
NCT04999644
Lorcaserin for Preventing Weight Gain Among Smokers
Mayo Clinic
NCT02393547
Brain Imaging in Tobacco Smokers During a Quit Attempt
Johns Hopkins University
NCT04055467
Varenicline Effects In Schizophrenic Smokers
Nathan Kline Institute for Psychiatric Research
NCT00548470
Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy
Hartford Hospital
NCT00888979
Role of Metabolites in Nicotine Dependence (2) - 5
National Institute on Drug Abuse (NIDA)
NCT00000288
Progesterone Treatment in Female Smokers - 12
National Institute on Drug Abuse (NIDA)
NCT00000295
Non-Nicotine Agents for Smoking Cessation
US Department of Veterans Affairs
NCT00108537
Role of Metabolites in Nicotine Dependence (1) - 1
National Institute on Drug Abuse (NIDA)
NCT00000284
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 26 |
| Phase 3 | 3 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Tobacco Use Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tobacco Use Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tobacco Use Disorder page
75 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Tobacco Use Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute on Drug Abuse (NIDA) sponsors the most Tobacco Use Disorder trials on record, review their full trial history before evaluating a specific study. See National Institute on Drug Abuse (NIDA)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tobacco Use Disorder condition card totals 75 registered trials; most-linked intervention Varenicline; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.